[go: up one dir, main page]

DK1685096T3 - Pentafluorsulfanyl-benzoylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som medikamenter indeholdende dem - Google Patents

Pentafluorsulfanyl-benzoylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som medikamenter indeholdende dem

Info

Publication number
DK1685096T3
DK1685096T3 DK04797535T DK04797535T DK1685096T3 DK 1685096 T3 DK1685096 T3 DK 1685096T3 DK 04797535 T DK04797535 T DK 04797535T DK 04797535 T DK04797535 T DK 04797535T DK 1685096 T3 DK1685096 T3 DK 1685096T3
Authority
DK
Denmark
Prior art keywords
benzoylguanidines
pentafluorosulfanyl
diagnostic
drug
preparation
Prior art date
Application number
DK04797535T
Other languages
Danish (da)
English (en)
Inventor
Heinz-Werner Kleemann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1685096T3 publication Critical patent/DK1685096T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
DK04797535T 2003-11-13 2004-11-03 Pentafluorsulfanyl-benzoylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som medikamenter indeholdende dem DK1685096T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10353202A DE10353202A1 (de) 2003-11-13 2003-11-13 Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PCT/EP2004/012393 WO2005047239A1 (de) 2003-11-13 2004-11-03 Pentafluorsulfanyl-benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament

Publications (1)

Publication Number Publication Date
DK1685096T3 true DK1685096T3 (da) 2007-10-22

Family

ID=34585094

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04797535T DK1685096T3 (da) 2003-11-13 2004-11-03 Pentafluorsulfanyl-benzoylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som medikamenter indeholdende dem

Country Status (38)

Country Link
EP (1) EP1685096B1 (es)
JP (1) JP4528304B2 (es)
KR (1) KR101262065B1 (es)
CN (1) CN100445265C (es)
AR (1) AR046620A1 (es)
AT (1) ATE368029T1 (es)
AU (1) AU2004288758B2 (es)
BR (1) BRPI0416487A (es)
CA (1) CA2551057C (es)
CR (1) CR8321A (es)
CY (1) CY1106868T1 (es)
DE (2) DE10353202A1 (es)
DK (1) DK1685096T3 (es)
DO (1) DOP2004001028A (es)
EC (1) ECSP066563A (es)
ES (1) ES2287788T3 (es)
GT (1) GT200400217A (es)
HN (1) HN2004000474A (es)
HR (1) HRP20070364T3 (es)
IL (1) IL175237A (es)
JO (1) JO2466B1 (es)
MA (1) MA28161A1 (es)
MY (1) MY144211A (es)
NI (1) NI200600112A (es)
NO (1) NO20062635L (es)
NZ (1) NZ547172A (es)
OA (1) OA13285A (es)
PE (1) PE20051034A1 (es)
PL (1) PL1685096T3 (es)
PT (1) PT1685096E (es)
RS (1) RS50520B (es)
RU (1) RU2380358C2 (es)
TN (1) TNSN06116A1 (es)
TW (1) TWI334411B (es)
UA (1) UA84307C2 (es)
UY (1) UY28616A1 (es)
WO (1) WO2005047239A1 (es)
ZA (1) ZA200602579B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317124B2 (en) 2003-11-13 2008-01-08 Sanofi-Aventis Deutschland Gmbh Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates
EP2242740B1 (de) 2008-02-05 2012-12-12 Sanofi Sf5-derivate als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
EP2661434A4 (en) * 2011-01-06 2014-07-09 Beta Pharma Canada Inc NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER
JPWO2015064764A1 (ja) 2013-11-01 2017-03-09 宇部興産株式会社 アリーロイル（オキシ又はアミノ）ペンタフルオロスルファニルベンゼン化合物、薬学的に許容されるその塩、及びそのプロドラッグ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0589336B1 (de) * 1992-09-22 1997-01-08 Hoechst Aktiengesellschaft Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19517848A1 (de) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorhaltige Benzoylguanidine
DE19526381A1 (de) * 1995-07-19 1997-01-23 Hoechst Ag 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19713427A1 (de) * 1997-04-01 1998-10-08 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19950898A1 (de) * 1999-10-22 2001-04-26 Aventis Pharma Gmbh Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10222192A1 (de) * 2002-05-18 2003-11-27 Aventis Pharma Gmbh Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10338554A1 (de) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
CA2551057A1 (en) 2005-05-26
JP2007513076A (ja) 2007-05-24
DE502004004460D1 (de) 2007-09-06
HRP20070364T3 (en) 2008-01-31
AU2004288758B2 (en) 2011-06-02
CY1106868T1 (el) 2012-09-26
IL175237A0 (en) 2006-09-05
RU2006120448A (ru) 2007-12-27
TNSN06116A1 (en) 2007-11-15
PT1685096E (pt) 2007-09-04
MY144211A (en) 2011-08-15
ES2287788T3 (es) 2007-12-16
HK1095584A1 (zh) 2007-05-11
DE10353202A1 (de) 2005-06-16
RU2380358C2 (ru) 2010-01-27
IL175237A (en) 2010-12-30
CN100445265C (zh) 2008-12-24
JO2466B1 (en) 2009-01-20
PE20051034A1 (es) 2005-12-23
ZA200602579B (en) 2007-06-27
OA13285A (en) 2007-01-31
JP4528304B2 (ja) 2010-08-18
BRPI0416487A (pt) 2007-03-27
MA28161A1 (fr) 2006-09-01
ATE368029T1 (de) 2007-08-15
TW200530162A (en) 2005-09-16
NI200600112A (es) 2006-12-12
CR8321A (es) 2007-09-14
DOP2004001028A (es) 2005-05-14
ECSP066563A (es) 2006-10-17
RS50520B (sr) 2010-05-07
NO20062635L (no) 2006-08-11
TWI334411B (en) 2010-12-11
KR101262065B1 (ko) 2013-05-08
HN2004000474A (es) 2009-06-19
EP1685096A1 (de) 2006-08-02
CN1878755A (zh) 2006-12-13
GT200400217A (es) 2005-06-23
UY28616A1 (es) 2005-06-30
AU2004288758A1 (en) 2005-05-26
CA2551057C (en) 2012-10-30
AR046620A1 (es) 2005-12-14
KR20060122848A (ko) 2006-11-30
UA84307C2 (ru) 2008-10-10
WO2005047239A1 (de) 2005-05-26
NZ547172A (en) 2009-12-24
EP1685096B1 (de) 2007-07-25
PL1685096T3 (pl) 2007-11-30

Similar Documents

Publication Publication Date Title
PL1730131T3 (pl) Glukopiranozylo-podstawione pochodne benzenu, środki lecznicze zawierające te związki, ich zastosowanie i sposób ich wytwarzania
DK1532149T3 (da) 8-[3-amino-piperiden-1-yl]-xanthiner, fremstilling deraf og anvendelse deraf som lægemiddel
NO20044322L (no) Benzoksanon-avledede forbindelser, deres fremstilling og anvendelse som medikament
DK1592457T3 (da) Folat-vinblastin-konjugat som lægemiddel
DK1562946T5 (da) Nye xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel
NO20090295L (no) Substituerte heteroarylderivater
DK2178881T3 (da) Hidtil ukendte 6-triazolopyridazin-sulfanyl-benzothiazol- og -benzimidazolderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler og farmaceutiske sammensætninger og hidtil ukendt anvendelse som met-hæmmere
DK1445252T3 (da) Sulfonamid-derivater, deres fremstilling og anvendelse som medikamenter
NO20054006D0 (no) Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer
DK1792927T3 (da) Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens
NO20052668D0 (no) Umiddelbart avgivende doseringsform som har kapsel med apninger i denne
NO20042805L (no) Nye forbindelser og deres anvendelse innen medisin, fremgangsmate for deres fremstilling og farmaoytiske sammensetninger som inneholder dem
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
DK1453810T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
NO20052683D0 (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20025635L (no) Anvendelse av biguanidderivater til fremstilling av et legemiddel som har en sarhelende virkning
NO20023643L (no) Forbindelser som har antitumoraktivitet, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholderdem
DK1838315T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til fremstilling heraf, deres anvendelse som medikament samt medikamenter indeholdende dem
NO20022801D0 (no) Substituerte norbornylaminoderivater, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikumsåvel som medikamenter inneholdende disse
DK1513834T3 (da) Substituerede thiophener, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikament, som indeholder dem
DK1509498T3 (da) Pentafloursulfanyl-benzoylguanidiner, fremgangsmåder til fremstilling deraf, anvendelse deraf som medikament eller diagnostikum samt medikament indeholdende dem
DK1685096T3 (da) Pentafluorsulfanyl-benzoylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som medikamenter indeholdende dem
NO20064808L (no) Orale matrixformuleringer med licarbazepin